A Philadelphia judge on Friday slashed an $8 billion jury verdict in a lawsuit over the marketing of the antipsychotic drug Risperdal, reducing the punitive damages to $6.8 million.

The verdict, in October, was the first to award punitive damages against Janssen Pharmaceuticals, a Johnson & Johnson subsidiary. It found that the company had played down the drug’s risks, which could lead to breast growth in boys.

The lawsuit was filed by a Maryland man, Nicholas Murray, who sued the company in 2013. He said that he grew breasts — a condition known as gynecomastia — after he began using Risperdal in 2003, at age 9, to treat symptoms of autism. The lawsuit accused Janssen of failing to warn doctors about Risperdal’s risks while improperly marketing it as a treatment for certain mental health disorders in children.

Compensatory damages of $680,000 were already awarded in the case in March 2016.

Judge Kenneth J. Powell Jr., of the Philadelphia Court of Common Pleas, dismissed other portions of Johnson & Johnson’s post-trial motion. Large jury verdicts are frequently reduced after trial.